All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
TORONTO – Industry-led accelerator Next Generation Manufacturing Canada (NGen) has dipped into its CA$50 million (US$37 million) supercluster fund to help three Canadian companies beef up the nation’s supply of COVID-19 equipment and medical devices.
TORONTO – Once he’d enrolled in an entrepreneurial engineering course, third-year medical school student Gabriel Georges’ task was deceptively simple: come up with a device to meet an unmet medical need. Before long, Georges had pulled two other students with engineering and investor relations smarts into the project, developing a minimally invasive, long-term transcatheter heart pump that this month garnered financing from Canadian and U.S. investors.
TORONTO – What do agricultural pesticides and concealed weapons have to do with med-tech advances in fighting COVID-19? Plenty, according to Canada’s science and industry ministry.
TORONTO – Vancouver, B.C.-based Sonic Incytes Medical Corp. is giving MRI a run for its money assessing chronic liver disease following a successful, CA$3.5 (US$2.6 million) seed round. That brings total funding to CA$8 million (US$5.92 million) for a hand-held ultrasound device that quantifies liver disease using 3D tissue sampling and analysis in approximately five minutes in a doctor’s office.
TORONTO – Toronto-based Epineuron Technologies Inc. reported the completion of a financing round to develop and clinically validate neuroregenerative technology intended for the recovery of patients suffering from peripheral nerve injuries. Designated a breakthrough device by the U.S. FDA, the “nerve bandage” uses brief bioelectronic stimulation of injured nerves to “upregulate” associated genes that accelerate nerve regeneration.
TORONTO – Seven years after setting up shop in downtown Toronto, high resolution, surgical imaging med-tech company Perimeter Medical Imaging Inc. (PMI) is still wrestling with a statistical heartbreaker: 1 in 4 patients told to return for a second surgery to remove cancerous breast tissue after the first surgery failed to get it all. Now PMI has said it can cut that number down dramatically thanks to a $7.44 million investment from the Austin, Texas-based Cancer Prevention and Research Institute of Texas (CPRIT) to identify wayward breast cancer cells using artificial intelligence technology.
TORONTO – Vancouver, British Columbia-based Izotropic Corp. has inked a deal with Victoria, British Columbia-based based Starfish Medical Inc. to commercialize a CT scanner Izotropic CEO Robert Thast said will be a major disruptor of the breast imaging industry. Izotropic has spent approximately $20 million over the past 15 years to develop the system and is counting on Starfish to help translate this into a market-ready 3D breast CT imager by the end of 2020.
Within a month of disclosing a CA$175.6 million (US$124.7 million) award from the Canadian government to use its antibody discovery platform for the analysis of patients who have recovered from COVID-19, Abcellera Biologics Inc. closed a $105 million series B financing aimed at expanding its capacity and investing in new technologies that complement its antibody discovery engine.
TORONTO – How confident is Canada’s government that Abcellera Biologics Inc. can identify viral antibodies to help stop COVID-19 in its tracks and build the manufacturing infrastructure for antibody therapies against future pandemic threats? Enough to award the Vancouver, British Columbia-based biotech CA$175.6 million (US$124.7 million) for the application of its antibody discovery platform to the analysis of patients who have recovered from COVID-19.
TORONTO – The Toraymyxin (PMX) hemoperfusion cartridge developed by Toronto’s Spectral Medical Inc. and used successfully to treat patients during the avian and swine flu pandemics is being eyed to help COVID-19 patients in Canada. Specifically, an emergency interim order from Health Canada expands its use to include treatment of COVID-19 patients with high levels of endotoxin in their blood and in acute respiratory failure.
